Skip to main content
Log in

Effect of vigabatrin and gabapentin on phynytoin pharmacokinetics in the dog

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The study was aimed at investigating whether or not the kinetics of intravenously administered phenytoin (PT) was altered by oral administration of vigabatrin (VGB) or gabapentin (GBP).

A group of five beagle dogs were given a daily dose of PT (12 mg/kg, i.v.) for a period of 1 week. On day 8, plasma samples were serially collected over 24 hr. after administration of the PT dose. PT administration was continued with oral supplementary dose of VGB (60 mg/kg) for another week and then plasma samples were collected for analysis of PT levels. The same protocol was followed for the PT (12 mg/kg, IV) — GBP (300 mg caps., PO) study on a separate group (n=5) of dogs.

Orally administered GBP did not significantly alter the pharmacokinetic parameters of parentral PT. VGB, however markedly changed the drug’s kinetics as evidenced by a 31% (P=0.015) reduction in total body clearance (CL) and increase of over 45% in half-life (t1/2), (P=0.013) and area under the plasma PT concentration-time curve (AUC), (P=0.044).

GBP does not appear to have any pharmacokinetic interaction with PT, while coadministration of VGB and PT results in marked reduction in systemic clearance of the latter in the dog.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Sabers A., Gram L. (1992): Pharmacology of vigabatrin. Pharmacol. Toxicol., 70, 237–243.

    Article  CAS  PubMed  Google Scholar 

  2. Schechter P. (1989): Clinical pharmacology of vigabatrin. Br. J. Clin. Pharmacol., 27, 19S-22S.

    CAS  PubMed  Google Scholar 

  3. Grant S., Heel R. (1991): Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs, 41, 889–926.

    Article  CAS  PubMed  Google Scholar 

  4. Elwes R., Binnie C. (1996): Clinical Pharmacokinetics of newer antiepileptic drugs: lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin. Pharmacokinet, 30, 403–415.

    Article  CAS  PubMed  Google Scholar 

  5. Rimmer E., Kongola G., Richens A. (1988): Inhibition of the enzyme GABA — aminotrannsferase in human platelets by vigabatrin. Br. J. Clin. Pharmacol., 25, 251–259.

    CAS  PubMed  Google Scholar 

  6. Andrews C., Fischer J. (1994): Gabapentin: a new agent for the management of epilepsy. Ann. Pharmacother, 28, 1188–1196.

    CAS  PubMed  Google Scholar 

  7. Petroff O., Rothman D., Behar K. (1996): The effect of gabapentin of brain γ-aminobutyric acid in patients with epilepsy. Ann. Neurol., 39, 95–99.

    Article  CAS  PubMed  Google Scholar 

  8. Rimmer E., Richens A. (1989): Interaction between vigabatrin and phenytoin. Br. J. Clin. Pharmacol., 27, 27S-33S.

    PubMed  Google Scholar 

  9. Browne T., Mattson R., Penry J., Smith D., Treiman D., Wilder B., Ben-Menachem E., Napoliello M., Sherry K., Szabo G. (1987): Vigabatrin for refractory complex partial seizures: multicentre single-blind study and long term follow-up. Neurol., 37, 187–189.

    Google Scholar 

  10. Tyndel F. (1994): Interaction of gabapentin with other antiepileptics (Letter). Lancet., 343, 1363–1364.

    Article  CAS  PubMed  Google Scholar 

  11. Anhut H., Leppik T., Schmidt B. (1988): Drug interaction study of the new anticonvulsant gabapentin with phenytoin in epileptic patients (abstract). Arch. Pharmacol., 337, R127.

    Google Scholar 

  12. Crawford P., Ghadiali E., Lane R., Blumhardt L., Chadwick D. (1987): Gabapenti as an antiepileptic drug in man. J. Neurol. Neurosurg. Psyychiatry, 50, 682–686.

    Article  CAS  Google Scholar 

  13. Gibaldi M., Perrier D. (eds). (1982). Pharmacokinnetics. 2nd edition. New York: Marcel Dekker.

    Google Scholar 

  14. Riva R., Albani F., Contin M., Baruzzi A. (1996): Pharmacokinetic interaction between antiepileptic drugs: Clinical considerations. Clin. Pharmacokinet., 31, 470–493.

    Article  CAS  PubMed  Google Scholar 

  15. Anderson G. (1998): A mechanistic approach to antiepileptic drug interactions. Ann. Pharmacother., 32, 554–563.

    Article  CAS  PubMed  Google Scholar 

  16. Richens A. (1991): Pharmacology and clinical pharmacology of vigabatrin. J. Child. Neurol., 6, 2S7–2S10.

    Article  Google Scholar 

  17. Hoensch H., Hutzel H., Kirch W., Ohnhaus E. (1985): Isolation of human hepatic microsomes and their inhibition by cimetidine and raintidine. Eur. J. Clin. Pharmacol. 29, 199–206.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matar, K.M., Nicholls, P.J., Tekle, A. et al. Effect of vigabatrin and gabapentin on phynytoin pharmacokinetics in the dog. Eur. J. Drug Metab. Pharacokinet. 25, 189–193 (2000). https://doi.org/10.1007/BF03192312

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03192312

Keywords

Navigation